Zydus’ ZYCUBO Wins Landmark USFDA Nod For Menkes Disease Therapy

's US subsidiary, Sentynl Therapeutics, has secured USFDA approval for ZYCUBO (copper histidinate), the first and currently only authorised treatment for Menkes disease in the United States, targeting pediatric patients with this ultra-rare genetic disorder of copper transport. Menkes disease, driven by ATP7A mutations, typically leads to severe neurodegeneration and death by two to three years of age when untreated. ZYCUBO is a subcutaneous injectable formulation engineered to restore and maintain systemic copper balance, addressing the underlying metabolic defect rather than only symptoms. Clinical data cited by the company indicate nearly an 80 percent reduction in risk of death with early ZYCUBO treatment versus an untreated external control group, with median overall survival extending to 177.1 months from 17.6 months in untreated patients, underscoring a substantial survival benefit. The asset, acquired from Cyprium Therapeutics in 2023, carries multiple US designations, including Breakthrough Therapy, Fast Track, Rare Pediatric Disease and Orphan Drug status, while copper histidinate also holds orphan designation from the European Medicines Agency, reinforcing its strategic value in the rare-disease portfolio. Management positions the approval as the culmination of decades of research and a key step in building a differentiated rare-disease franchise. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.